Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

3-Substituted N-Benzylpyrazine-2-carboxamide Derivatives: Synthesis, Antimycobacterial and Antibacterial Evaluation

L. Semelková, O. Janďourek, K. Konečná, P. Paterová, L. Navrátilová, F. Trejtnar, V. Kubíček, J. Kuneš, M. Doležal, J. Zitko,

. 2017 ; 22 (3) : . [pub] 20170321

Language English Country Switzerland

Document type Journal Article

A series of substituted N-benzyl-3-chloropyrazine-2-carboxamides were prepared as positional isomers of 5-chloro and 6-chloro derivatives, prepared previously. During the aminolysis of the acyl chloride, the simultaneous substitution of chlorine with benzylamino moiety gave rise to N-benzyl-3-(benzylamino)pyrazine-2-carboxamides as side products, in some cases. Although not initially planned, the reaction conditions were modified to populate this double substituted series. The final compounds were tested against four mycobacterial strains. N-(2-methylbenzyl)-3-((2-methylbenzyl)amino)pyrazine-2-carboxamide (1a) and N-(3,4-dichlorobenzyl)-3-((3,4-dichlorobenzyl)amino)pyrazine-2-carboxamide (9a) proved to be the most effective against Mycobacterium tuberculosis H37Rv, with MIC = 12.5 μg·mL(-1). Compounds were screened for antibacterial activity. The most active compound was 3-chloro-N-(2-chlorobenzyl)pyrazine-2-carboxamide (5) against Staphylococcus aureus with MIC = 7.81 μM, and Staphylococcus epidermidis with MIC = 15.62 μM. HepG2 in vitro cytotoxicity was evaluated for the most active compounds; however, no significant toxicity was detected. Compound 9a was docked to several conformations of the enoyl-ACP-reductase of Mycobacterium tuberculosis. In some cases, it was capable of H-bond interactions, typical for most of the known inhibitors.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023185
003      
CZ-PrNML
005      
20240528081236.0
007      
ta
008      
170720s2017 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/molecules22030495 $2 doi
035    __
$a (PubMed)28335571
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Semelková, Lucia $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. semelkol@faf.cuni.cz.
245    10
$a 3-Substituted N-Benzylpyrazine-2-carboxamide Derivatives: Synthesis, Antimycobacterial and Antibacterial Evaluation / $c L. Semelková, O. Janďourek, K. Konečná, P. Paterová, L. Navrátilová, F. Trejtnar, V. Kubíček, J. Kuneš, M. Doležal, J. Zitko,
520    9_
$a A series of substituted N-benzyl-3-chloropyrazine-2-carboxamides were prepared as positional isomers of 5-chloro and 6-chloro derivatives, prepared previously. During the aminolysis of the acyl chloride, the simultaneous substitution of chlorine with benzylamino moiety gave rise to N-benzyl-3-(benzylamino)pyrazine-2-carboxamides as side products, in some cases. Although not initially planned, the reaction conditions were modified to populate this double substituted series. The final compounds were tested against four mycobacterial strains. N-(2-methylbenzyl)-3-((2-methylbenzyl)amino)pyrazine-2-carboxamide (1a) and N-(3,4-dichlorobenzyl)-3-((3,4-dichlorobenzyl)amino)pyrazine-2-carboxamide (9a) proved to be the most effective against Mycobacterium tuberculosis H37Rv, with MIC = 12.5 μg·mL(-1). Compounds were screened for antibacterial activity. The most active compound was 3-chloro-N-(2-chlorobenzyl)pyrazine-2-carboxamide (5) against Staphylococcus aureus with MIC = 7.81 μM, and Staphylococcus epidermidis with MIC = 15.62 μM. HepG2 in vitro cytotoxicity was evaluated for the most active compounds; however, no significant toxicity was detected. Compound 9a was docked to several conformations of the enoyl-ACP-reductase of Mycobacterium tuberculosis. In some cases, it was capable of H-bond interactions, typical for most of the known inhibitors.
650    _2
$a antibakteriální látky $x chemická syntéza $x chemie $x farmakologie $7 D000900
650    _2
$a buňky Hep G2 $7 D056945
650    _2
$a lidé $7 D006801
650    _2
$a mikrobiální testy citlivosti $7 D008826
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a molekulární struktura $7 D015394
650    _2
$a Mycobacterium tuberculosis $x účinky léků $7 D009169
650    _2
$a pyraziny $x chemická syntéza $x chemie $x farmakologie $7 D011719
650    _2
$a Staphylococcus aureus $x účinky léků $7 D013211
650    _2
$a Staphylococcus epidermidis $x účinky léků $7 D013212
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
655    _2
$a časopisecké články $7 D016428
700    1_
$a Janďourek, Ondřej $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. JANDO6AA@faf.cuni.cz.
700    1_
$a Konečná, Klára $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. konecna@faf.cuni.cz.
700    1_
$a Paterová, Pavla $u Department of Clinical Microbiology, University Hospital, Sokolská 581, 500 05 Hradec Králové, Czech Republic. pavla.paterova@fnhk.cz.
700    1_
$a Navrátilová, Lucie $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. navratl2@faf.cuni.cz.
700    1_
$a Trejtnar, František $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. trejtnarf@faf.cuni.cz.
700    1_
$a Kubíček, Vladimír $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. kubicek@faf.cuni.cz.
700    1_
$a Kuneš, Jiří $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. kunes@faf.cuni.cz.
700    1_
$a Doležal, Martin, $d 1961- $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. dolezalm@faf.cuni.cz. $7 jn19981000714
700    1_
$a Zitko, Jan $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. jan.zitko@faf.cuni.cz.
773    0_
$w MED00180394 $t Molecules $x 1420-3049 $g Roč. 22, č. 3 (2017)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28335571 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20240528081234 $b ABA008
999    __
$a ok $b bmc $g 1238866 $s 984098
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 22 $c 3 $e 20170321 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
LZP    __
$a Pubmed-20170720

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...